Plain words for a Charlotte peptide-care search
Is this an approved drug or something else?
Ask for the exact medicine name, its form and who supplies it. The word “peptide” leaves too much unanswered.
Ask what the label will actually say.
An approved medicine has a specific record
The FDA application records, checked September 26, 2026, include semaglutide products (Ozempic, Wegovy) with approval, along with approved tirzepatide products (Mounjaro, Zepbound). Ask which exact product is proposed and for what purpose.
An NDC is a number identifying a product in the FDA’s drug directory; FDA approval does not follow from having that number, as of September 26, 2026. Ask to see approval for the exact medicine rather than accepting its listing number as proof.
Compounding needs its own explanation
Compounding involves preparing a medicine to order, either by making it or changing it. As of September 26, 2026, compounded medicines go on sale without FDA review of quality, safety or how well the medicines work.
The FDA’s compounding guidance says it may serve a need an approved product cannot meet. Ask which need applies to you and how this preparation would address it.
Why ask about a compounded copy?
As of September 26, 2026, federal law generally bars a pharmacist or doctor from routinely making a near-copy of a medicine already on sale. A changed version falls outside that copy restriction if the prescriber decides the change makes a meaningful difference for one named patient. For example, FDA describes compounding for someone allergic to a dye in the factory-made medicine. Paying less, by itself, is not the meaningful difference required.
When FDA’s national shortage list was checked on September 26, 2026, it contained neither semaglutide nor tirzepatide. That means a national shortage no longer provides a reason to make copies of these medicines under the shortage rules. Ask your prescriber to name the change you need and explain why it is outside the copy restriction.
Research labels and prescription limits
In letters checked as of September 26, 2026, FDA treated some research-labelled peptide products as unapproved drugs because they were promoted for human use. In one warning letter, FDA said the seller’s website showed that the products were meant for people despite their research labels.
A warning letter says what FDA believes a company did wrong; it is not a court’s final decision. If you see a research label, ask the service to explain what it is offering.
A prescription does not answer every question
In FDA’s guidance checked as of September 26, 2026, federal law forbids using retatrutide or cagrilintide to compound medicine. A prescription does not remove that ban.
If a service cannot explain the proposed product clearly, leave that question open before making a decision.